Table 4.
Frequency of Reports of Drowsiness/Sedataion during 6-Week Exposure to Olanzapine
| Drowsiness | Mild percentage | Moderate/severe percentage |
|---|---|---|
| Week 1 | 58.3% | 8.3% |
| Week 2 | 58.3% | 25.0% |
| Week 3 | 58.3% | 25.0% |
| Week 4 | 75.0% | 0.0% |
| Week 5 | 75.0% | 0.0% |
| Week 6 | 83.3% | 16.7% |
| Cumulative percentages (all weeks) | 100.0% | 50.0% |
Percentage of patients who reported drowsiness as a side effect, separated by week and severity of symptom. Cumulative percentage refers to all patients from all weeks who reported drowsiness as a side effect (n = 12).